Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Phathom Pharmaceuticals, Inc. - Common Stock (NQ:PHAT)

13.76 +0.26 (+1.93%)
Streaming Delayed Price Updated: 3:01 PM EST, Jan 26, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 670,213
Open 13.44
Bid (Size) 13.77 (100)
Ask (Size) 13.80 (100)
Prev. Close 13.50
Today's Range 13.14 - 14.06
52wk Range 2.210 - 18.31
Shares Outstanding 43,614,075
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Phathom Pharma Shows Sales Strength, Targets 2026 Profitability ↗
Phathom Pharmaceuticals (NASDAQ: PHAT) reported Q4 sales of $57-$58 million, updated FY2025 revenue guidance to $174.5-$175.5 million. 
Via Benzinga
Get insights into the top gainers and losers of Thursday's pre-market session. ↗
Via Chartmill

Performance

YTD
-12.4%
-12.4%
1 Month
-21.6%
-21.6%
3 Month
-0.4%
-0.4%
6 Month
+56.4%
+56.4%
1 Year
+109.8%
+109.8%

More News

Read More
News headline image
Phathom Pharmaceuticals Announces Pricing of $130 Million Public Offering of Common Stock and Pre-Funded Warrants
From Phathom Pharmaceuticals
Via GlobeNewswire
News headline image
Earnings Scheduled For October 30, 2025 ↗
Via Benzinga
News headline image
Earnings Scheduled For August 7, 2025 ↗
Via Benzinga
Stay updated with the stocks that are on the move in today's after-hours session. ↗
Via Chartmill
News headline image
Phathom Pharmaceuticals Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
From Phathom Pharmaceuticals
Via GlobeNewswire
News headline image
Phathom Pharmaceuticals Announces Preliminary Fourth Quarter and Full Year 2025 Financial Results
From Phathom Pharmaceuticals
Via GlobeNewswire
News headline image
PHATHOM PHARMACEUTICALS INC (NASDAQ:PHAT) Shows Strong Growth and Momentum Alignment with Minervini Strategy ↗
Via Chartmill
News headline image
High Growth Momentum and Technical Strength Drive PHATHOM PHARMACEUTICALS INC (NASDAQ:PHAT) ↗
Via Chartmill
News headline image
Phathom Pharmaceuticals Announces First Patient Dosed in Phase 2 Study of VOQUEZNA® (vonoprazan) in Eosinophilic Esophagitis (EoE)
From Phathom Pharmaceuticals
Via GlobeNewswire
News headline image
Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences
From Phathom Pharmaceuticals
Via GlobeNewswire
News headline image
Phathom Pharmaceuticals (NASDAQ:PHAT) Surpasses Q3 2025 Earnings Estimates and Raises Full-Year Guidance ↗
Via Chartmill
Topics Earnings
News headline image
Phathom Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Business Update
From Phathom Pharmaceuticals
Via GlobeNewswire
News headline image
Phathom Pharmaceuticals Announces Publication of Data from Phase 3 pHalcon-NERD-301 Study Showing VOQUEZNA® (vonoprazan) Improved Nocturnal GERD Symptoms in Patients with Non-Erosive Reflux Disease
From Phathom Pharmaceuticals
Via GlobeNewswire
News headline image
Phathom Pharmaceuticals to Highlight VOQUEZNA® (vonoprazan) at the American College of Gastroenterology (ACG) 2025 Annual Scientific Meeting
From Phathom Pharmaceuticals
Via GlobeNewswire
News headline image
Phathom Pharmaceuticals to Report Third Quarter 2025 Financial Results and Provide Business Update on Thursday, October 30, 2025
From Phathom Pharmaceuticals
Via GlobeNewswire
News headline image
Phathom Pharmaceuticals Appoints Sanjeev Narula as Chief Financial and Business Officer
From Phathom Pharmaceuticals
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Wednesday's After-Market Session ↗
Via Benzinga
News headline image
Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences
From Phathom Pharmaceuticals
Via GlobeNewswire
News headline image
Phathom Pharmaceuticals Clarifies That There Is No Reduction in Lead Shareholder’s Ownership Following Administrative Change to 13D Filing
From Phathom Pharmaceuticals
Via GlobeNewswire
News headline image
Phathom (PHAT) Q2 Revenue Jumps 441% ↗
Via The Motley Fool
News headline image
Phathom Pharmaceuticals (NASDAQ:PHAT) Surpasses Q2 Estimates with Strong VOQUEZNA Growth, Shares Jump 6% in Premarket ↗
Via Chartmill
News headline image
Phathom Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Updates
From Phathom Pharmaceuticals
Via GlobeNewswire
News headline image
Phathom Pharmaceuticals to Report Second Quarter 2025 Financial Results and Provide Business Update on Thursday, August 7, 2025
From Phathom Pharmaceuticals
Via GlobeNewswire

Frequently Asked Questions

Is Phathom Pharmaceuticals, Inc. - Common Stock publicly traded?
Yes, Phathom Pharmaceuticals, Inc. - Common Stock is publicly traded.
What exchange does Phathom Pharmaceuticals, Inc. - Common Stock trade on?
Phathom Pharmaceuticals, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Phathom Pharmaceuticals, Inc. - Common Stock?
The ticker symbol for Phathom Pharmaceuticals, Inc. - Common Stock is PHAT on the Nasdaq Stock Market
What is the current price of Phathom Pharmaceuticals, Inc. - Common Stock?
The current price of Phathom Pharmaceuticals, Inc. - Common Stock is 13.76
When was Phathom Pharmaceuticals, Inc. - Common Stock last traded?
The last trade of Phathom Pharmaceuticals, Inc. - Common Stock was at 01/26/26 03:01 PM ET
What is the market capitalization of Phathom Pharmaceuticals, Inc. - Common Stock?
The market capitalization of Phathom Pharmaceuticals, Inc. - Common Stock is 600.13M
How many shares of Phathom Pharmaceuticals, Inc. - Common Stock are outstanding?
Phathom Pharmaceuticals, Inc. - Common Stock has 600M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.